MELODY
Nirsevimab for Prevention of RSV in Healthy Infants
Patient / Population Intervention / Exposure Comparison Outcome
In 1,490 healthy late-preterm and term infants, a single intramuscular dose of nirsevimab reduced medically attended RSV-associated lower-respiratory-tract infection compared with placebo.
N
1,490
Design
Double-blind RCT
Endpoint
Medically attended RSV-LRTI
Relevance
3
Result1.2 % vs 5.0 %; efficacy 74.5 %.
Hammitt LL, et al. N Engl J Med. 2022;386(9):837-846. 10.1056/NEJMoa2110275
Discussion & critique
Established universal infant RSV monoclonal prophylaxis — now standard in many countries during the RSV season.